IRLAB Therapeutics AB (IRLAB A):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:IRLAB Therapeutics AB (IRLAB A) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8220
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
IRLAB Therapeutics AB (IRL) is a pharmaceutical company that discovers and develops drugs to treat central nervous system associated diseases. The company conducts flagship technology integrative screening process, a phenotypic screening and systems pharmacology process is used for development its therapeutic products. Its products comprise IRL790 for treating parkinson disease psychosis and L-dopa induced dyskinesias in parkinson’s disease, IRL752 for treatment of dementia, IRL626 for treating schizophrenia, P001 for treating attention disorders, and IRL448 and IRL555. It offers development of drugs to assist patients with Parkinson’s disease. IRL is headquartered in Gothenburg, Sweden.

IRLAB Therapeutics AB (IRLAB A) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
IRLAB Therapeutics Raises USD3.5 Million in Venture Financing 10
Partnerships 11
IRLAB Therapeutics Enters into Agreement with Clinical Trial 11
Equity Offering 12
IRLAB Therapeutics Raises USD16 Million in Private Placement of Shares 12
IRLAB Therapeutics Raises USD12.9 Million in IPO 14
IRLAB Therapeutics Raises USD13 Million in Rights Offering of Shares 15
IRLAB Therapeutics AB – Key Competitors 16
IRLAB Therapeutics AB – Key Employees 17
IRLAB Therapeutics AB – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Aug 29, 2017: IRLAB Interim Report April-June 2017 19
May 16, 2017: IRLAB Therapeutics Interim Report January-March 2017 21
Feb 27, 2017: IRLAB Therapeutics Year-end report for 2016 23
Corporate Communications 26
Sep 20, 2017: Nomination committee appointed in IRLAB 26
Jun 30, 2017: IRLAB appoints new CFO and recruits researchers 27
Apr 24, 2017: Nomination Committee’s proposal for a Board of Directors of IRLAB Therapeutics 28
Product News 29
Sep 19, 2018: IRLAB nominates two new candidate drugs and updates the pipeline 29
Clinical Trials 31
Aug 30, 2018: IRLAB reports promising efficacy data from Phase IIa-study with IRL752 31
Jun 29, 2018: IRLAB reports top-line results from Phase IIa study with IRL752 32
Jan 31, 2018: IRLAB Provides Update On Clinical Phase II pipeline – IRL752 33
Jan 31, 2018: IRLAB Provides Update On Clinical Phase II pipeline – IRL790 35
Nov 15, 2017: IRLAB receives MHRA approval to conduct Phase II trials with IRL790 in Britain 37
Oct 05, 2017: IRLAB receives approval from the Finnish MPA (Fimea) 38
Oct 04, 2017: IRLAB starts Phase II study with IRL752 for the treatment of Parkinson’s disease dementia 39
Aug 25, 2017: IRLAB receives approval to initiate Phase II trials with IRL752 40
May 24, 2017: IRLAB patent application for large-scale production method 41
May 15, 2017: IRLAB announces positive results from study with IRL790 42
Mar 16, 2017: IRLAB Therapeutics reports positive results from clinical phase 1 studies for IRL752 and includes agreements to conduct Phase 2 studies 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
IRLAB Therapeutics AB, Deals By Therapy Area, 2012 to YTD 2018 8
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
IRLAB Therapeutics Raises USD3.5 Million in Venture Financing 10
IRLAB Therapeutics Enters into Agreement with Clinical Trial 11
IRLAB Therapeutics Raises USD16 Million in Private Placement of Shares 12
IRLAB Therapeutics Raises USD12.9 Million in IPO 14
IRLAB Therapeutics Raises USD13 Million in Rights Offering of Shares 15
IRLAB Therapeutics AB, Key Competitors 16
IRLAB Therapeutics AB, Key Employees 17

List of Figures
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[IRLAB Therapeutics AB (IRLAB A):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mangalam Drugs and Organics Ltd (MANGALAM):企業の財務・戦略的SWOT分析
    Summary Mangalam Drugs and Organics Ltd (MDOL) carries out manufacturing and supplying of specialty chemicals, intermediates, and active pharmaceutical ingredients. The company's active pharmaceutical ingredients include amodiaquine HCl, bisoprolol fumarate, artemether, dihydroartemisinin, hydroxy c …
  • China International Travel Service Corporation Limited:企業の戦略・SWOT・財務分析
    China International Travel Service Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China International Travel Service Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Tejas Networks Ltd (TEJASNET):企業の財務・戦略的SWOT分析
    Tejas Networks Ltd (TEJASNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • XState Resources Ltd (XST):企業の財務・戦略的SWOT分析
    Summary XState Resources Ltd (XST) is an oil and gas exploration and development company. The company’s business activities include acquisition, exploration, production and development of oil and gas assets. It holds interest in producing gas wells and associated land leases and production and pipel …
  • Owens & Minor Inc (OMI):医療機器:M&Aディール及び事業提携情報
    Summary Owens & Minor Inc (Owens & Minor) is a healthcare services company, which provides supply chain services to healthcare providers and manufacturers of healthcare products. It provides logistics services for disposable medical supplies, devices and implants. Owens & Minor offers medical and su …
  • Intermountain Healthcare Inc:企業の戦略的SWOT分析
    Intermountain Healthcare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • CRH public limited company (CRG):企業の財務・戦略的SWOT分析
    CRH public limited company (CRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Celldex Therapeutics, Inc.:企業の戦略・SWOT・財務分析
    Celldex Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Celldex Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ryman Healthcare Ltd (RYM):企業の財務・戦略的SWOT分析
    Ryman Healthcare Ltd (RYM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Eagle Bancorp Inc:企業の戦略・SWOT・財務分析
    Eagle Bancorp Inc - Strategy, SWOT and Corporate Finance Report Summary Eagle Bancorp Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Electronic Arts Inc.:企業の戦略・SWOT・財務情報
    Electronic Arts Inc. - Strategy, SWOT and Corporate Finance Report Summary Electronic Arts Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Koninklijke Ten Cate NV:企業の戦略的SWOT分析
    Koninklijke Ten Cate NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Sinopac Financial Holdings Company Limited
    Sinopac Financial Holdings Company Limited - Strategy, SWOT and Corporate Finance Report Summary Sinopac Financial Holdings Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Conco, Inc.:企業の戦略・SWOT・財務情報
    Conco, Inc. - Strategy, SWOT and Corporate Finance Report Summary Conco, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Yantai Dongcheng Pharmaceutical Group Co Ltd (002675):製薬・医療:M&Aディール及び事業提携情報
    Summary Yantai Dongcheng Pharmaceutical Group Co Ltd (Yantai Dongcheng Pharma), formerly Yantai Dongcheng Biochemicals Co Ltd, is a developer, manufacturer, and marketer of biochemical API, chemical synthetic drugs, and Chinese medicines. The company offers its products under categories including he …
  • Perrigo Company Plc (PRGO):医療機器:M&Aディール及び事業提携情報
    Summary Perrigo Company plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic and prescription pharmaceuticals, specialty pharmaceutical company, nutritional products, active pharmaceutic …
  • GS Retail Co., Ltd. (007070):企業の財務・戦略的SWOT分析
    GS Retail Co., Ltd. (007070) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Koninklijke Wessanen N.V.:企業の戦略・SWOT・財務情報
    Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report Summary Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Audi AG (NSU):企業の財務・戦略的SWOT分析
    Audi AG (NSU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Sompo Japan Nipponkoa Holdings, Inc.:戦略・SWOT・企業財務分析
    Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆